Read the latest insights and research related to graft-versus-host disease (GVHD). GVHD is a complication post-transplant where the donor's immune cells attack the recipient's tissues.
Rovadicitinib demonstrates therapeutic potential for patients whose chronic graft-versus-host disease (cGVHD) is glucocorticoid-refractory or -dependent, researchers report.
Study findings support the oral microbiome as a potential pathway for preventing or managing chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation (HCT).